The “Transitional Coverage for Emerging Technologies” (TCET) offering is a slightly watered-down version of the reimbursement plan proposed earlier this year.
Marks the first & only blood test granted FDA marketing authorization for prognostication of disease progression in patients with advanced fibrosis due to NASH.
In a pilot study treating refractory epilepsy with Neuroelectrics’ Starstim platform, patients experienced a 44 percent median reduction in seizure frequency.
The algorithm monitors hospitalized patients and can predict acute kidney injury more than a full day before patients meet the clinical criteria for diagnosis.
The Acclaim device offers the benefits of traditional partially implanted cochlear implants without the external components and associated disadvantages.